Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease

被引:23
|
作者
Facchinetti, Fabrizio [1 ]
Civelli, Maurizio [1 ]
Singh, Dave [2 ]
Papi, Alberto [3 ]
Emirova, Aida [4 ]
Govoni, Mirco [4 ]
机构
[1] Corp Preclin R&D, Parma, Italy
[2] Manchester Univ NHS Fdn Hosp Trust, Med Evaluat Unit, Manchester, Lancs, England
[3] Univ Ferrara, Dept Translat Med, Resp Med, Ferrara, Italy
[4] Global Clin Dev, Parma, Italy
关键词
phosphodiesterase 4 inhibitors (PDE4i); asthma; COPD-chronic obstructive pulmonary disease; inhaled administration; inflammation; SURFACTANT PROTEIN-D; METERED-DOSE INHALER; PHOSPHODIESTERASE-4; INHIBITOR; EOSINOPHILIC INFLAMMATION; PRECLINICAL PHARMACOLOGY; TRIPLE THERAPY; CYCLIC-AMP; ROFLUMILAST; COPD; CHF6001;
D O I
10.3389/fphar.2021.740803
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chronic respiratory diseases are the third leading cause of death, behind cardiovascular diseases and cancer, affecting approximately 550 million of people all over the world. Most of the chronic respiratory diseases are attributable to asthma and chronic obstructive pulmonary disease (COPD) with this latter being the major cause of deaths. Despite differences in etiology and symptoms, a common feature of asthma and COPD is an underlying degree of airways inflammation. The nature and severity of this inflammation might differ between and within different respiratory conditions and pharmacological anti-inflammatory treatments are unlikely to be effective in all patients. A precision medicine approach is needed to selectively target patients to increase the chance of therapeutic success. Inhibitors of the phosphodiesterase 4 (PDE4) enzyme like the oral PDE4 inhibitor roflumilast have shown a potential to reduce inflammatory-mediated processes and the frequency of exacerbations in certain groups of COPD patients with a chronic bronchitis phenotype. However, roflumilast use is dampened by class related side effects as nausea, diarrhea, weight loss and abdominal pain, resulting in both substantial treatment discontinuation in clinical practice and withdrawal from clinical trials. This has prompted the search for PDE4 inhibitors to be given by inhalation to reduce the systemic exposure (and thus optimize the systemic safety) and maximize the therapeutic effect in the lung. Tanimilast (international non-proprietary name of CHF6001) is a novel highly potent and selective inhaled PDE4 inhibitor with proven anti-inflammatory properties in various inflammatory cells, including leukocytes derived from asthma and COPD patients, as well as in experimental rodent models of pulmonary inflammation. Inhaled tanimilast has reached phase III clinical development by showing promising pharmacodynamic results associated with a good tolerability and safety profile, with no evidence of PDE4 inhibitors class-related side effects. In this review we will discuss the main outcomes of preclinical and clinical studies conducted during tanimilast development, with particular emphasis on the characterization of the pharmacodynamic profile that led to the identification of target populations with increased therapeutic potential in inflammatory respiratory diseases.
引用
收藏
页数:18
相关论文
共 50 条
  • [31] Bronchoscopic treatment of asthma and chronic obstructive pulmonary disease
    Schuhmann, Maren
    PNEUMOLOGE, 2020, 17 (01): : 22 - 27
  • [32] Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study
    Singh, Dave
    Emirova, Aida
    Francisco, Catherine
    Santoro, Debora
    Govoni, Mirco
    Nandeuil, Marie Anna
    RESPIRATORY RESEARCH, 2020, 21 (01)
  • [33] Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study
    Dave Singh
    Aida Emirova
    Catherine Francisco
    Debora Santoro
    Mirco Govoni
    Marie Anna Nandeuil
    Respiratory Research, 21
  • [34] Safety, tolerability and pharmacokinetics of CHF 6001, a novel selective inhaled PDE4 inhibitor, in healthy volunteers
    Lucci, Germano
    Mariotti, Fabrizia
    Santoro, Debora
    Acerbi, Daniela
    Poli, Gianluigi
    Nandeuil, Marie-Anna
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [35] PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease
    Banner, KH
    Trevethick, MA
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2004, 25 (08) : 430 - 436
  • [36] Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis
    Abdulrahim, Hunar
    Thistleton, Samuel
    Adebajo, Adewale O.
    Shaw, Tim
    Edwards, Christopher
    Wells, Alvin
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (07) : 1099 - 1108
  • [37] The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAs
    Nguyen, Hoang Oanh
    Schioppa, Tiziana
    Tiberio, Laura
    Facchinetti, Fabrizio
    Villetti, Gino
    Civelli, Maurizio
    Del Prete, Annalisa
    Sozio, Francesca
    Gaudenzi, Carolina
    Passari, Mauro
    Barbazza, Ilaria
    Sozzani, Silvano
    Salvi, Valentina
    Bosisio, Daniela
    FRONTIERS IN IMMUNOLOGY, 2022, 12
  • [38] Responsiveness to inhaled corticosteroid treatment in patients with asthma-chronic obstructive pulmonary disease overlap syndrome
    Lim, Hyo Seok
    Choi, Sun Mi
    Lee, Jinwoo
    Park, Yong Sik
    Lee, Sang-Min
    Yim, Jae-Joon
    Yoo, Chul-Gyu
    Kim, Young Whan
    Han, Sung Koo
    Lee, Chang-Hoon
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2014, 113 (06) : 652 - 657
  • [39] Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor Apremilast
    Krase, Ifat Zerin
    Cavanaugh, Kevin
    Curiel-Lewandrowski, Clara
    JAMA DERMATOLOGY, 2016, 152 (03) : 348 - 350
  • [40] An inhibitor of RORγ for chronic pulmonary obstructive disease treatment
    Desai, Harshada
    Marathe, Megha
    Potdar, Varada
    Tiwari, Prabhakar
    Joshi, Ashwini
    Kadam, Sheetal R.
    Joshi, Arti Rajesh
    Kulkarni, Abhay
    Bhosale, Vikram
    Hadambar, Avinash
    Lodhiya, Bhavik
    Udupa, Venkatesha
    Behera, Dayanidhi
    Chaudhari, Sachin S.
    Das, Sanjib
    Bajpai, Malini
    Gowda, Nagaraj
    Iyer, Pravin S.
    SCIENTIFIC REPORTS, 2022, 12 (01)